Ota-ku, Japan

Momoko Ogitani

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 14.9

ph-index = 3

Forward Citations = 18(Granted Patents)


Location History:

  • Ota-ku, JP (2020 - 2023)
  • Tokyo, JP (2024)

Company Filing History:


Years Active: 2020-2024

Loading Chart...
Loading Chart...
7 patents (USPTO):

Title: Momoko Ogitani: Innovator in Pharmaceutical Chemistry

Introduction

Momoko Ogitani is a prominent inventor based in Ota-ku, Japan. She has made significant contributions to the field of pharmaceutical chemistry, holding a total of seven patents. Her work focuses on developing compounds with therapeutic applications, particularly in the treatment of inflammatory diseases.

Latest Patents

Among her latest patents is a Griseofulvin compound, which aims to provide a compound with anti-inflammatory activity or a pharmacologically acceptable salt thereof. This invention includes a compound of general formula (1), where specific symbols represent various chemical groups, such as C1-C6 alkyl groups and oxygen atoms. Another notable patent involves a urea compound with a specific chemical structure that activates SIRT6, making it useful for preventing and treating inflammatory diseases. This invention also relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof.

Career Highlights

Momoko Ogitani is currently employed at Daiichi Sankyo Company, Limited, where she continues to innovate in the pharmaceutical sector. Her research and inventions have the potential to impact the treatment of various inflammatory conditions, showcasing her dedication to improving healthcare through scientific advancements.

Collaborations

She has collaborated with notable colleagues, including Keiji Saito and Katsuyoshi Nakajima, further enhancing her research and development efforts in the field.

Conclusion

Momoko Ogitani's contributions to pharmaceutical chemistry through her innovative patents highlight her role as a leading inventor in her field. Her work continues to pave the way for advancements in the treatment of inflammatory diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…